Minirin (Desmopressin Acetate)

Desmopressin acetate, the active ingredient in Minirin, is a vasopressin analog presented as a nasal spray for nasal administration. It is used to manage central diabetes insipidus and primary nocturnal enuresis by reducing excessive urine production in patients who lack adequate endogenous antidiuretic hormone.

GNH USA supplies Minirin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑approved documentation for global distribution.

Desmopressin acts on the antidiuretic hormone pathway to control water balance.

- Central diabetes insipidus: reduces polyuria and normalizes plasma osmolality. - Primary nocturnal enuresis: decreases nighttime urine volume and improves continence.

Desmopressin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nasal irritation or congestion. - Headache. - Mild nausea. - Epistaxis (nosebleed).

Serious or Rare Side Effects: - Hyponatraemia leading to seizures or coma. - Water intoxication with cerebral oedema. - Allergic reactions such as rash or angio‑edema. - Nasal septum perforation with prolonged use.

Before prescribing Desmopressin, clinicians should consider several safety measures.

- Assess serum sodium before initiating: monitor for hyponatraemia. - Avoid in patients with uncontrolled hyponatraemia: risk of water intoxication. - Use with caution in renal impairment: reduced clearance may increase exposure. - Limit fluid intake as directed: helps prevent dilutional hyponatraemia. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Desmopressin can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: reduces desmopressin effectiveness. - MAO inhibitors: increase risk of hyponatraemia. - Concurrent antidiuretics: additive antidiuretic effect may cause severe water retention.

Moderate Interactions (Monitor Closely): - NSAIDs: may potentiate antidiuretic activity. - SSRIs: can increase hyponatraemia risk. - Thiazide diuretics: may exacerbate low sodium levels.